Filing Details

Accession Number:
0001209191-21-068510
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-08 16:05:35
Reporting Period:
2021-11-23
Accepted Time:
2021-12-08 16:05:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1806310 Taysha Gene Therapies Inc. TSHA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1701846 Ii R.a. Session C/O Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Suite 1430
Dallas TX 75247
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-23 16,510 $12.12 9,164,912 No 4 P Direct
Common Stock Acquisiton 2021-11-23 26,008 $12.65 9,190,920 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 141,090 Indirect See footnote
Common Stock 141,090 Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.46 to $12.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2).
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.46 to $12.94 inclusive.
  3. The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
  4. The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.